Publication Name	World Journal of Gastroenterology
Manuscript ID	9639
Country	Taiwan

Received	2014-02-21 21:36
Peer-Review Started	2014-02-23 18:42
To Make the First Decision	2014-06-18 17:23
Return for Revision	2014-06-22 19:00
Revised	2014-07-04 15:57
Second Decision	2014-08-28 09:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-08-28 10:04
Articles in Press	2014-08-28 10:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-06 19:01
Publish the Manuscript Online	2014-11-20 20:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	CYP2C19 polymorphism influences Helicobacter pylori eradication
Manuscript Source	Invited Manuscript
All Author List	Chao-Hung Kuo, Chien-Yu Lu, Hsiang-Yao Shih, Chung-Jung Liu, Meng-Chieh Wu, Huang-Ming Hu, Wen-Hung Hsu, Fang-Jung Yu, Deng-Chyang Wu and Fu-Chen Kuo
Funding Agency and Grant Number	Funding Agency Grant Number Kaohsiung Medical University “Aim for the Top Universities Grant KMU-TP103G01 Kaohsiung Medical University “Aim for the Top Universities Grant KMU-TP103 G04 (partially)
Corresponding Author	Fu-Chen Kuo, PhD, School of Medicine, College of Medicine, E-Da Hospital, I-Shou University, No.1, Yida Rd., Yanchao Shiang, Kaohsiung 824, Taiwan. fuchenkuotw@yahoo.com.tw
Key Words	Helicobacter pylori; CYP2C19; Polymorphism; Eradication; Rabeprazole; Omeprazole; Lansoprazole; Pantoprazole; Esomeprazole
Core Tip	This manuscript outlines the impact of CYP2C19 polymorphism on eradication of Helicobacter pylori (H. pylori), including the influences on first line triple therapies, rescue therapies and levofloxacin- based therapies. We suggest that the strategy of eradicating H. pylori should include the examination of CYP2C19 polymorphism, especially for patients receiving rescue therapies or with drug resistances.
Publish Date	2014-11-20 20:51
Citation	Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20(43): 16029-16036
URL	http://www.wjgnet.com/1007-9327/full/v20/i43/16029.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i43.16029

Full Article (PDF)	WJG-20-16029.pdf
Full Article (Word)	WJG-20-16029.doc
Manuscript File	9639-Review.docx
Answering Reviewers	9639-Answering reviewers.pdf
Copyright License Agreement	9639-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	9639-Language certificate.pdf
Peer-review Report	9639-Peer review(s).pdf
Scientific Misconduct Check	9639-CrossCheck.jpg
Scientific Editor Work List	9639-Scientific editor work list.pdf